This webinar has since taken place and is now available on-demand.
About the Webinar
Antisense oligonucleotide (ASO) technology has accelerated drug discovery in the last few decades with several ASO-based drugs currently approved by FDA and many more being investigated in clinical trials.
Chemical modifications to ASOs affect their physical and chemical properties, helping researchers design more efficient and potent ASO-based drugs.
This webinar will explore the most recent ASO chemical modification: locked nucleic acid (LNA), which confers high potency. Our expert speakers will provide insights into the critical in vitro and in vivo steps involved in the characterization of an oligonucleotide with LNA chemistry.
In this webinar, you will:
- Learn about a pharmacokinetic/pharmacodynamic model for the main organs of oligonucleotide accumulation and elimination
- Discover the screening cascade applied for selection of the optimal ASO
- Learn how to evaluate the pharmacokinetic characteristics of a LNA ASO
